| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 4, 2014Employee Engagement, Philanthropy Among Top Reasons for Selection
BRAMPTON, ONTARIO - November 4, 2014 - Medtronic of Canada Ltd., a trusted Canadian leader in innovative medical technologies and health system solutions, is pleased to have been recognized as one...
-
Nov 4, 2014Consistent Outcomes Despite Common and Challenging Comorbidity Reinforce Overall Findings of IN.PACT SFA Trial
LAS VEGAS -- Nov. 4, 2014 -- For the treatment of peripheral artery disease in leg arteries above the knee, the IN.PACT Admiral drug-coated balloon from Medtronic, Inc. (NYSE: MDT) provided a...
-
Nov 4, 2014The HawkOne™ System strengthens Covidien’s directional atherectomy platform with a versatile solution for the treatment of peripheral arterial disease
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 4, 2014-- Covidien plc (NYSE: COV) today announced U.S. Food and Drug Administration 510(k) clearance for the HawkOne™ directional atherectomy system. The...
-
Nov 4, 2014Results suggest long-term benefits for peripheral artery disease patients treated with directional atherectomy followed by a drug-coated balloon
LAS VEGAS--(BUSINESS WIRE)--Nov. 4, 2014-- Covidien plc (NYSE: COV) today announced 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical...
-
Nov 2, 2014Expands Spectranetics' portfolio of solutions to treat complex vascular conditions in projected $700 million drug coated balloon segment
COLORADO SPRINGS, Colo., and DUBLIN, Ireland, Nov. 2, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) and Covidien plc (NYSE:COV) today announced a definitive agreement under...